npc1

npc1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">npc1</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Variable (infantile, juvenile, adult)</td>
</tr>
<tr>
<td class="label">Neurological</td>
<td>Ataxia, dystonia, seizures, vertical supranuclear gaze palsy</td>
</tr>
<tr>
<td class="label">Systemic</td>
<td>Hepatosplenomegaly, cholestatic jaundice</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Progressive dementia, learning disabilities</td>
</tr>
<tr>
<td class="label">Death</td>
<td>Usually in second or third decade</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">p.I1061T</td>
<td>Missense, severe</td>
</tr>
<tr>
<td class="label">p.P1007A</td>
<td>Missense, mild</td>
</tr>
<tr>
<td class="label">p.G992W</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">p.L724P</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.3182delC</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">IVS21+1G>A</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampu

npc1

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">npc1</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Variable (infantile, juvenile, adult)</td>
</tr>
<tr>
<td class="label">Neurological</td>
<td>Ataxia, dystonia, seizures, vertical supranuclear gaze palsy</td>
</tr>
<tr>
<td class="label">Systemic</td>
<td>Hepatosplenomegaly, cholestatic jaundice</td>
</tr>
<tr>
<td class="label">Cognitive</td>
<td>Progressive dementia, learning disabilities</td>
</tr>
<tr>
<td class="label">Death</td>
<td>Usually in second or third decade</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">p.I1061T</td>
<td>Missense, severe</td>
</tr>
<tr>
<td class="label">p.P1007A</td>
<td>Missense, mild</td>
</tr>
<tr>
<td class="label">p.G992W</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">p.L724P</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">c.3182delC</td>
<td>Frameshift</td>
</tr>
<tr>
<td class="label">IVS21+1G>A</td>
<td>Splicing</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">White Matter</td>
<td>High</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">103 edges</a></td>
</tr>
</table>

Npc1 Gene Niemann Pick C1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The NPC1 gene (Niemann-Pick C1) located at chromosome 18q11.2 encodes a critical intracellular cholesterol transporter that plays a central role in cellular lipid homeostasis^[1]. Mutations in NPC1 cause Niemann-Pick disease type C (NPC), a fatal neurodegenerative lysosomal storage disorder characterized by accumulation of cholesterol and glycolipids in cells throughout the body^[2]. The NPC1 protein is essential for the transport of cholesterol from late endosomes/lysosomes to other cellular compartments^[3]. NPC1 is responsible for approximately 95% of NPC cases, with NPC2 accounting for the remaining 5%^[1]. [@patterson2012]

Function

Cholesterol Trafficking

NPC1 is a multipass transmembrane protein localized to the limiting membrane of late endosomes and lysosomes. It functions as a key transporter in the late endosomal/lysosomal (LE/LY) system^[4]: [@lloydevans2015]

• Cholesterol Export: Facilitates efflux of unesterified cholesterol from LE/LY to the endoplasmic reticulum and plasma membrane
• Lipid Sorting: Involved in trafficking of other lipids including glycolipids and sphingolipids
• Endosomal Maturation: Essential for proper late endosome function and trafficking
• [Autophagy](/entities/autophagy): Critical for the autophagic-lysosomal pathway^[5]

Molecular Mechanism

The NPC1 protein contains several functional domains^[6]: [@walkley2013]

• Sterol-sensing domain (SSD): Recognizes cholesterol and other sterols
• N-terminal domain (NTD): Binds cholesterol and delivers it to the transporter
• Transmembrane domains: Form the channel for cholesterol transit
• Cysteine-rich domain (CRD): Involved in protein-protein interactions

Physiological Roles

• Cellular Cholesterol Homeostasis: Essential for maintaining cellular cholesterol balance
• Myelin Formation: Critical for oligodendrocyte function and myelination^[8]
• Synaptic Function: Important for neuronal synaptic vesicle trafficking
• Immune Function: Regulates macrophage lipid content and function
• Autophagy: Essential for autophagosome-lysosome fusion^[5]

Disease Associations

Niemann-Pick Disease Type C

NPC is an autosomal recessive lysosomal storage disorder with devastating neurological manifestations^[2]: [@hughes2018]

Biallelic pathogenic variants in NPC1 lead to loss of function, causing accumulation of unesterified cholesterol, glucosylceramide, and gangliosides in lysosomes. This triggers lysosomal dysfunction, inflammatory response, and neuronal [apoptosis](/entities/apoptosis)^[1]. [@polo2021]

Neurodegeneration

The NPC1 dysfunction has implications beyond NPC^[9]:

• Alzheimer's Disease: NPC1 function affects amyloid processing; reduced NPC1 in AD brains^[10]
• Parkinson's Disease: Some PD patients carry NPC1 variants; shared lysosomal dysfunction^[11]
• Huntington's Disease: Altered cholesterol metabolism in HD
• Multiple System Atrophy: Lysosomal dysfunction common to both conditions

Common Variants

Over 500 pathogenic variants have been identified in NPC1, with the majority being missense mutations^[1].

Expression Patterns

• Tissue Distribution: Ubiquitous; highest in liver, brain, and lung
• Brain Expression: [Neurons](/entities/neurons), [astrocytes](/entities/astrocytes), oligodendrocytes, [microglia](/entities/microglia)
• Cellular Localization: Late endosome/lysosome limiting membrane
• Subcellular: Also on Golgi and plasma membrane
• Regulation: Upregulated by cholesterol depletion

Allen Brain Atlas Data

Gene Expression

• Cerebral cortex - Moderate expression in pyramidal neurons
• Hippocampus - Moderate-high expression in CA1-CA3 neurons
• Cerebellum - Moderate expression in Purkinje cells
• Basal ganglia - Moderate expression in striatum
• White matter - High expression in oligodendrocytes

Single-Cell Expression

• Highest expression in oligodendrocytes (cholesterol trafficking)
• High expression in astrocytes
• Moderate expression in neurons
• Lower expression in microglia

Cell Type Specific Expression

• Oligodendrocytes: Highest expression (myelin cholesterol metabolism)
• Astrocytes: High expression (cholesterol homeostasis)
• Neurons: Moderate expression
• Microglia: Low-moderate expression

Brain Region Expression Table

Therapeutic Targeting

FDA-Approved Therapies (2024)

The treatment landscape for NPC has evolved significantly with three FDA-approved therapies^[1]:

• Miglustat (Zavesca): First approved therapy for NPC, reduces glycolipid accumulation by inhibiting glucosylceramide synthase. Approved in multiple countries and shown to stabilize neurological progression^[12]
• Arimoclomol (Miplyffa): FDA-approved September 2024 for use with miglustat for neurologic manifestations in persons age ≥2 years. Acts as a molecular chaperone to stabilize NPC1 protein function^[13]
• Levacetylleucine (Aqneursa): FDA-approved September 2024 as a standalone treatment for adults and children weighing ≥15 kg. Improves neurological symptoms by stabilizing the NPC1 protein^[13]

Experimental Approaches

• Cholesterol-Reducing Agents: 2-hydroxypropyl-beta-cyclodextrin (HPβCD) being investigated; intravenous trials showed 7/9 participants improved^[14]
• Gene Therapy: AAV-vector delivery in clinical trials^[8]
• Substrate Reduction Therapy: Reducing substrate accumulation
• Stem Cell Therapy: Being explored for neurological symptoms
• Antisense Oligonucleotides: Targeting specific mutations

Interaction Network

NPC1 interacts with multiple proteins in lipid trafficking and lysosomal function:

• NPC2 (Niemann-Pick C2) - Cholesterol binding and transfer partner^[7]
• LDL Receptor - Cholesterol uptake
• [ApoE](/proteins/apoe-protein) - Lipid transport in the brain^[10]
• [mTOR](/entities/mtor) - Nutrient sensing pathway
• Rab proteins - Vesicle trafficking
• GBA (Glucocerebrosidase) - Shared lysosomal pathway with Parkinson's disease^[11]

Research Directions

Mechanistic Role in Alzheimer's Disease

The link between NPC1 dysfunction and Alzheimer's disease has been extensively studied in recent years. The cholesterol trafficking pathway modulated by NPC1 plays a critical role in amyloid precursor protein (APP) processing and amyloid-beta (Aβ) generation[vRu2019].

Cholesterol-Regulated Amyloid Processing

Cellular cholesterol levels directly influence APP trafficking and proteolytic processing. When NPC1 function is impaired, the resulting lysosomal cholesterol accumulation disrupts multiple cellular pathways:

• APP trafficking: Cholesterol-enriched membranes affect APP localization to lipid rafts, favoring amyloidogenic β-secretase cleavage
• BACE1 activity: Higher cholesterol facilitates BACE1 access to APP, increasing Aβ production
• γ-secretase modulation: Altered membrane composition affects γ-secretase complex assembly and activity
• Aβ clearance: NPC1 dysfunction impairs autophagy-lysosomal Aβ degradation[@schur2019]

Evidence from Human Brain Studies

Post-mortem studies of AD brains reveal:

• Reduced NPC1 expression in temporal cortex and hippocampus
• Decreased lysosomal NPC1 protein levels correlate with disease severity
• Shared lysosomal storage abnormalities between NPC and AD brains

Therapeutic Implications for AD

Understanding the NPC1-cholesterol-Aβ axis has led to therapeutic strategies:

• Cholesterol-lowering agents (statins) show mixed results in clinical trials
• Autophagy-enhancing compounds (rapamycin, trehalose) under investigation
• Combination approaches targeting both cholesterol and autophagy

Mechanistic Role in Parkinson's Disease

NPC1 dysfunction shares significant overlap with Parkinson's disease pathogenesis, particularly in lysosomal protein degradation pathways[giraldo2020].

Alpha-Synuclein Accumulation

Both NPC and PD involve:

• Lysosomal dysfunction leading to protein accumulation
• Impaired autophagosome-lysosome fusion
• Endoplasmic reticulum stress responses
• Oxidative stress and mitochondrial dysfunction

Shared Genetic Susceptibility

Studies have identified:

• Heterozygous NPC1 variants in some PD patients
• Shared lysosomal storage phenotypes
• Common therapeutic targets (GBA, LAMP2)

LRRK2 Interaction

Evidence suggests crosstalk between NPC1 and LRRK2 (leucine-rich repeat kinase 2), a major PD-causative gene:

• LRRK2 regulates lysosomal function
• Altered lysosomal cholesterol may affect LRRK2 membrane localization
• Combined therapeutic targeting is being explored

Mermaid Diagram: NPC1 in Cellular Cholesterol Trafficking

Background

The study of Npc1 Gene Niemann Pick C1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Niemann-Pick Disease](/diseases/niemann-pick-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Cholesterol Metabolism](/mechanisms/cerebral-cholesterol-metabolism)
• [Genetics of Neurodegenerative Diseases](/mechanisms/genetics)

Pathway Diagram

The following diagram shows the key molecular relationships involving npc1 discovered through SciDEX knowledge graph analysis: